Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CDA | P32320 | 1/20 | 0.42 |
| ▸ | HK1 | P19367 | 2/20 | 0.40 |
| ▸ | HK2 | P52789 | 2/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL19357416 | 0.76 | CDA (0.54) | MAPTCDAHK1HK2ALDH1A1 | |
| Ribose (Furanose) SCHEMBL10777150 | 0.76 | MAPT (0.41) | MAPTCDAHK1HK2SLC5A2 | |
| Ribose (Furanose) SCHEMBL4087975 | 0.73 | CDA (0.39) | MAPTCDAHK1HK2ALDH1A1 | |
| Ribose (Furanose) SCHEMBL5139187 | 0.73 | PYGL (0.47) | HK1HK2PYGLSLC5A2 | |
| Ribose (Furanose) SCHEMBL27934652 | 0.73 | PYGL (0.47) | HK1HK2PYGLSLC5A2 | |
| Anthraquinone SCHEMBL5981663 | 0.73 | MEN1 (0.53) | MAPTHK1HK2SLC5A2MEN1 | |
| Ribose (Furanose) SCHEMBL16703138 | 0.72 | SLC28A3 (0.47) | HK1HK2SLC5A2 | |
| B-D-Galactose SCHEMBL15768434 | 0.72 | PYGL (0.49) | PYGLSLC5A2 | |
| Dextrose SCHEMBL3220374 | 0.72 | PYGL (0.49) | PYGLSLC5A2 | |
| Ribose (Furanose) SCHEMBL18788526 | 0.72 | MAPT (0.41) | MAPTCDAHK1HK2PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197766-A1 | TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE | THE CLEVELAND CLINIC FOUNDATION | 2024-06-20 | — | — | US | claimed |
| EP-4313069-A1 | TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE DEAMINASE INHIBITOR | The Cleveland Clinic Foundation (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022204126-A1 | TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE DEAMINASE INHIBITOR | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-09-29 | — | — | WO | claimed |
| US-20240197766-A1 | TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE | THE CLEVELAND CLINIC FOUNDATION | 2024-06-20 | — | — | US | disclosed |
| EP-4313069-A1 | TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE DEAMINASE INHIBITOR | The Cleveland Clinic Foundation (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204126-A1 | TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE DEAMINASE INHIBITOR | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-2381780-B1 | COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF | UNIV ILLINOIS (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100081621-A1 | Crystal structure of the catalytic domain of the viral restriction factor APOBEC3G | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-04-01 | — | — | US | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| WO-2005115410-A2 | CONTEXT DEPENDENT INHIBITORS OF CYTIDINE DEAMINASES AND USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-0703787-A1 | CELL GROWTH REGULATORS | NYCOMED PHARMA AS (NO) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994027632-A1 | CELL GROWTH REGULATORS | NYCOMED PHARMA A/S (NO) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | MAPT 4065/4885CDA 2/4885HK1 2569/4885 |
| US-20240197766-A1 | TREATMENT OF RNA VIRUS INFECTION WITH A CYTIDINE | NSUN2, DUT, APOBEC3G | MAPT 2142/4885CDA 10/4885HK1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.